A Dosing Study of Intravitreal Bevacizumab for Retinopathy of Prematurity

A Dosing Study of Two Different Doses (0.3125mg Versus 0.625mg) Intravitreal Bevacizumab for Type 1 ROP (Retinopathy of Prematurity)

The aim of our study was to determine whether a low dose of 0.3125mg intravitreal bevacizumab is effective in treatment of type 1 ROP as the standard 0.625 mg dose., regarding :

Serum Systemic VEGF levels. Retinal Vascularization.

Inclusion Criteria:

Infants with Type 1 ROP according to ETROP study which is defined as:

• Zone I ROP with plus disease
• Zone I, stage 3 ROP without plus disease
• Zone II, stage 2 or 3 ROP with plus disease

Exclusion Criteria:

• Eyes with previous intravitreal injection
• Eyes with previous laser therapy
• Eyes with any other intraocular pathology other than ROP (congenital cataract, congenital glaucoma, any retinal pathology other than ROP)